About Clinuvel
Clinuvel is a publicly listed company based in Melbourne (Australia) founded in 2001. Biopharmaceutical drugs for skin disorders are developed by Clinuvel. Its website clinuvel.com draws about 12 thousand monthly visits. Clinuvel offers products and services including CYACÊLLE Radiant and Pharmaceutical Products. Its focus areas include Life Sciences, Dermatology, Drugs and Aesthetics. Its legal entity is CLINUVEL Pharmaceuticals Ltd.
Company details
Clinuvel was founded in 2001 and is headquartered in Melbourne, Australia. Operations in the biopharmaceutical sector center on drug development for skin conditions. The lead product, Scenesse, addresses erythropoietic protoporphyria and the pigmentary disorder vitiligo. Additional melanocortin-based compounds, CUV9900 and VLRX001, are being advanced through subsidiary Vallaurix in preclinical stages.
- Annual Revenue$64.75 M (USD)-1.05as on Jun 30, 2026
- Net Profit$23.36 M (USD)-6.24as on Jun 30, 2026
- EBITDA$28.65 M (USD)-2.1as on Jun 30, 2026
- Latest Funding Round$6.26M (USD), Post-IPO
Mar 2016
Products & Services of Clinuvel
Clinuvel offers a comprehensive portfolio of products and services, including CYACÊLLE Radiant and Pharmaceutical Products.
Provides luxury skincare with triple light protection for skin health.
Develops therapies for severe medical needs in skin and brain disorders.
Apps and channels of Clinuvel
its YouTube channel CLINUVEL has 429 subscribers and 30 videos.
Videos from Clinuvel
The most watched videos on Clinuvel's YouTube channel, CLINUVEL (429 subscribers). Click a video to play it here.
More on CLINUVEL.
Funding Insights of Clinuvel
- Total Rounds 6
- Last Round Post-IPO — $6.26M
- First Round $3.71M
(Dec 2006)
All 6 funding rounds of Clinuvel with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2016 | $6.26M | Post-IPO | – | – | – |
| May 2014 | $6.74M | Post-IPO | – | – | – |
| May 2013 | $6.5M | Post-IPO | – | – | – |
| Jun 2012 | $6.24M | Post-IPO | – | – | – |
| Apr 2007 | $21.62M | Post-IPO | – | – | – |
| Dec 2006 | $3.71M | Post-IPO | – | – | – |
People of Clinuvel
22 people are tracked at Clinuvel (8 in leadership, 5 in board & advisors, 9 in team).
| Name | Role | Group |
|---|---|---|
Darren Keamy | Chief Financial Officer & Company Secretary | Leadership |
Philippe Wolgen | Managing Director and Chief Executive Officer | Leadership |
Dennis Wright | Chief Scientific Officer | Leadership |
Parijat Kanaujia | Vice President, Injectable Product Development | Leadership |
Antonella Colucci | Vice President, Commercial Affairs | Leadership |
Michael Turpin | Head of Digital Services | Leadership |
Azza HAMILA | Head of Quality & Drug Safety | Leadership |
Genevieve Tay | Vice President, Communications | Leadership |
Karen Agersborg | Non-executive Director | Board & advisors |
Jeffrey V. Rosenfeld | Non-executive Director | Board & advisors |
Brenda Shanahan | Non-executive Director | Board & advisors |
Susan Smith | Non-executive Director | Board & advisors |
Willem Blijdorp | Non-executive Chairman | Board & advisors |
Katie Hood | Senior Brand Manager | Team |
Kathleen McInerney | Scientific Affairs Project Manager | Team |
Kate Henschel | Accounts Receivable And Banking Officer | Team |
Bin Wang | Scientific Affairs | Team |
Sobana Kenneth | Finance Analyst | Team |
Gus Snarskis | Senior Digital Marketing Manager | Team |
Laure Hampton | Senior Quality Manager | Team |
2 more people are available in the full profile.
Complete people profiles for Clinuvel
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Clinuvel
Clinuvel is a publicly listed company on the ASX with ticker symbol CUV in Australia, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Feb 2001
- Listed onASX: CUV
- Listed entityCLINUVEL PHARMACEUTICALS LIMITED
- Exchange sectorHealth technology
- ISINAU000000CUV3
- Share price7.61 AUD (-2.06% on the day) · 2026-10-14
- Market capitalisation392,284,963.00 AUD
- Price to earnings11.4
- EPS (diluted, trailing year)0.67 AUD
- Dividend yield0.64%
- Volume (last session)155,063
Financials of Clinuvel
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2026 | 94.0M AUD | 33.9M AUD | 41.6M AUD |
| 2025 | 95.0M AUD | 36.2M AUD | 42.5M AUD |
| 2024 | 88.2M AUD | 35.6M AUD | 44.7M AUD |
| 2023 | 78.3M AUD | 30.6M AUD | 41.7M AUD |
| 2022 | 65.7M AUD | 20.9M AUD | 33.8M AUD |
Detailed financial statements for Clinuvel
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Clinuvel
4 dated milestones of Clinuvel across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Clinuvel is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $3.7M.
- Funding Latest funding round, Post-IPO, of $6.3M.
Web traffic of Clinuvel
The website of Clinuvel (clinuvel.com) receives about 12.3K visits a month and ranks #2,198,948 among all websites worldwide, #2,986 in Biotechnology and Pharmaceuticals.
- Monthly visits12.3K
▲ 14.4% vs previous month
- Unique visitors4.7K
per month
- Global rank#2,198,948
among all websites
- Category rank#2,986
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.6
- Average visit14 sec
- DevicesDesktop 29% · Mobile 71%
Websites whose visitors overlap most with Clinuvel. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| vitiligocover.com | 100% | #8,769,465 | View details | ||
baxterhealthcare.com.au | baxterhealthcare.com.au | 92% | #4,021,193 | – | |
womensderm.org | womensderm.org | 84% | #3,376,710 | – | |
| avitamedical.com | 84% | 7.6K | #2,907,382 | View details | |
ilds.org | ilds.org | 83% | #1,813,423 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 16 similar websites and full traffic analytics for Clinuvel
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 16 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Clinuvel
Complete news archive for Clinuvel
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Clinuvel
Clinuvel was founded in 2001 and raised its 1st funding round 5 years after it was founded.
Clinuvel is headquartered in Melbourne, Australia. It is registered at Melbourne, Victoria, Australia.
Annual revenue of Clinuvel is $64.75M as on Jun 30, 2026.
Clinuvel was founded in 2001 and is headquartered in Melbourne, Australia. Operations in the biopharmaceutical sector center on drug development for skin conditions. The lead product, Scenesse, addresses erythropoietic protoporphyria and the pigmentary disorder vitiligo. Additional melanocortin-based compounds, CUV9900 and VLRX001, are being advanced through subsidiary Vallaurix in preclinical stages.
Clinuvel offers CYACÊLLE Radiant and Pharmaceutical Products.
Yes, Clinuvel is publicly traded on ASX under the ticker symbol CUV.
Clinuvel operates through Clinuvel Pharmaceuticals Ltd.